Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
United States
National Institutes of Health, Bethesda, Maryland Last updated December 2025